Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol, a potential Stargardt disease treatment.
Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors
Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its…
Bristol-Myers Squibb's Stock Reaction to AstraZeneca Merger Denial Amid Market Surge
Bristol-Myers Squibb's stock dips as AstraZeneca merger talks are denied, contrasting with a bullish…
Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its…
Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impac…
Eton Pharmaceuticals Expands Portfolio with ASN-001 Acquisition
Eton Pharmaceuticals enhances its pipeline with the acquisition of ASN-001, targeting the infantile …
Bullish Surge: Nasdaq 100 Signals Market Optimism
The Nasdaq 100's top-10 bullish signal marks a pivotal moment for traders, with tech stocks leading …
Johnson & Johnson's Robotic Surgery Breakthrough: A Game Changer for Investors
FDA approval of J&J's OTTAVA system sparks optimism, positioning the company as a strong contender i…
Palantir's AI Surge: What Investors Need to Know After Q2 Earnings
Palantir's Q2 earnings show a strong 16% share price increase and highlight growing demand for enter…